BEAM
What one share of Beam Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities.
Beam Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.51 |
|---|---|
| Profit | −$0.84 |
| Capex (buildings and equipment) | $0.13 |
| Free cash flow | −$3.61 |
| Cash and investments | $11.16 |
| Debt | $0.97 |
| Book value | $10.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$14.05 | $1.93 | −$13.04 | — | −$27.45 |
| 2020 | — | −$4.19 | $0.35 | −$2.40 | — | $4.29 |
| 2021 | $0.81 | −$5.77 | $0.73 | −$1.76 | — | $12.09 |
| 2022 | $0.87 | −$4.13 | $0.70 | −$0.38 | — | $10.29 |
| 2023 | $4.90 | −$1.72 | $0.44 | −$2.37 | — | $12.02 |
| 2024 | $0.77 | −$4.58 | $0.11 | −$4.33 | — | $8.77 |
| 2025 | $1.41 | −$0.81 | $0.15 | −$3.64 | — | $12.17 |